Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-214,000
Closed -$42.3M 1231
2024
Q3
$42.3M Buy
214,000
+30,300
+16% +$5.65M 0.09% 121
2024
Q2
$31.5M Buy
183,700
+15,700
+9% +$2.6M 0.07% 168
2024
Q1
$30.6M Sell
168,000
-105,500
-39% -$18.2M 0.06% 176
2023
Q4
$42.4M Buy
273,500
+13,000
+5% +$1.9M 0.07% 158
2023
Q3
$38.8M Buy
+260,500
New +$38.2M 0.07% 156

Other funds holding ABBV

GTS Securities's ABBV Position: Q1 2026 in Review

GTS Securities reduced its AbbVie (ABBV) stake by 66% in Q1 2026, selling an estimated $2.74M and leaving 6,393 shares worth $1.39M. The position accounts for 0.05% of the portfolio, ranked #282.

GTS Securities first reported a position in ABBV in Q3 2023 and has held it in 11 quarters since. The position peaked at $14.7M in Q4 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • GTS Securities held 6,393 shares of AbbVie worth $1.39M as of Q1 2026.
  • GTS Securities sold 12,357 AbbVie shares in Q1 2026, an estimated $2.74M.
  • AbbVie made up 0.05% of GTS Securities's portfolio in Q1 2026, its #282 holding.
  • GTS Securities first reported a position in AbbVie in Q3 2023 and has held it in 11 quarters since.
  • GTS Securities's AbbVie position peaked at $14.7M in Q4 2023.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.